Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth

M. B. Judkins, M. I. Chernin, Satoru Nishimoto, P. Cassoni, G. Bussolati, K. Page, J. F. Novak

Research output: Contribution to journalArticle

Abstract

Tumor metastatic cells possess a cell-membrane-bound plasminogen activator system. We found that plasmin can cleave the bone-specific protein osteocalcin at arg43-arg44 releasing a carboxy terminal hexapeptide. We tested the biological effect of the C-terminal RFYGPV peptide in MG-63, U2OS, OS9 and OS15 osteosarcoma (OS) cells and found variable growth-promoting effects. Since the sequence of the C-peptide matched the EII region of the oxytocin receptor, we evaluated the OS cells for their response to oxytocin and established a strong growth inhibition by this peptide. This growth effect was substantiated by demonstration, using RT-PCR, of oxytocin receptors (OTR) in OS cells. The presence of OTR was also indicated by immunohistochemical methods. Osteocalcin C-peptide reversed the growth inhibition, however no interaction between oxytocin and C-peptide could be established by several methods aimed to resolve protein-protein interactions. Our results suggest that the plasminogen activator system may participate in the metastatic spread of oxytocin-sensitive tumor cells into skeletal sites by releasing a peptide from the bone protein osteocalcin which interferes with the growth-suppressing inhibition of oxytocin.

Original languageEnglish (US)
JournalFASEB Journal
Volume12
Issue number5
StatePublished - Mar 20 1998

Fingerprint

Osteocalcin
Cell growth
Oxytocin
Osteosarcoma
Oxytocin Receptors
C-Peptide
Peptides
Growth
Plasminogen Activators
Tumors
Bone
Proteins
Bone and Bones
Fibrinolysin
Cell membranes
Neoplasms
Demonstrations
Cells
Cell Membrane
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Judkins, M. B., Chernin, M. I., Nishimoto, S., Cassoni, P., Bussolati, G., Page, K., & Novak, J. F. (1998). Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth. FASEB Journal, 12(5).

Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth. / Judkins, M. B.; Chernin, M. I.; Nishimoto, Satoru; Cassoni, P.; Bussolati, G.; Page, K.; Novak, J. F.

In: FASEB Journal, Vol. 12, No. 5, 20.03.1998.

Research output: Contribution to journalArticle

Judkins, MB, Chernin, MI, Nishimoto, S, Cassoni, P, Bussolati, G, Page, K & Novak, JF 1998, 'Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth', FASEB Journal, vol. 12, no. 5.
Judkins, M. B. ; Chernin, M. I. ; Nishimoto, Satoru ; Cassoni, P. ; Bussolati, G. ; Page, K. ; Novak, J. F. / Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth. In: FASEB Journal. 1998 ; Vol. 12, No. 5.
@article{9b7ccc6f3f34410f96608aaed1cd7645,
title = "Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth",
abstract = "Tumor metastatic cells possess a cell-membrane-bound plasminogen activator system. We found that plasmin can cleave the bone-specific protein osteocalcin at arg43-arg44 releasing a carboxy terminal hexapeptide. We tested the biological effect of the C-terminal RFYGPV peptide in MG-63, U2OS, OS9 and OS15 osteosarcoma (OS) cells and found variable growth-promoting effects. Since the sequence of the C-peptide matched the EII region of the oxytocin receptor, we evaluated the OS cells for their response to oxytocin and established a strong growth inhibition by this peptide. This growth effect was substantiated by demonstration, using RT-PCR, of oxytocin receptors (OTR) in OS cells. The presence of OTR was also indicated by immunohistochemical methods. Osteocalcin C-peptide reversed the growth inhibition, however no interaction between oxytocin and C-peptide could be established by several methods aimed to resolve protein-protein interactions. Our results suggest that the plasminogen activator system may participate in the metastatic spread of oxytocin-sensitive tumor cells into skeletal sites by releasing a peptide from the bone protein osteocalcin which interferes with the growth-suppressing inhibition of oxytocin.",
author = "Judkins, {M. B.} and Chernin, {M. I.} and Satoru Nishimoto and P. Cassoni and G. Bussolati and K. Page and Novak, {J. F.}",
year = "1998",
month = "3",
day = "20",
language = "English (US)",
volume = "12",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "5",

}

TY - JOUR

T1 - Interaction between osteocalcin carboxyterminal peptide and oxytocin in regulation of osteosarcoma cell growth

AU - Judkins, M. B.

AU - Chernin, M. I.

AU - Nishimoto, Satoru

AU - Cassoni, P.

AU - Bussolati, G.

AU - Page, K.

AU - Novak, J. F.

PY - 1998/3/20

Y1 - 1998/3/20

N2 - Tumor metastatic cells possess a cell-membrane-bound plasminogen activator system. We found that plasmin can cleave the bone-specific protein osteocalcin at arg43-arg44 releasing a carboxy terminal hexapeptide. We tested the biological effect of the C-terminal RFYGPV peptide in MG-63, U2OS, OS9 and OS15 osteosarcoma (OS) cells and found variable growth-promoting effects. Since the sequence of the C-peptide matched the EII region of the oxytocin receptor, we evaluated the OS cells for their response to oxytocin and established a strong growth inhibition by this peptide. This growth effect was substantiated by demonstration, using RT-PCR, of oxytocin receptors (OTR) in OS cells. The presence of OTR was also indicated by immunohistochemical methods. Osteocalcin C-peptide reversed the growth inhibition, however no interaction between oxytocin and C-peptide could be established by several methods aimed to resolve protein-protein interactions. Our results suggest that the plasminogen activator system may participate in the metastatic spread of oxytocin-sensitive tumor cells into skeletal sites by releasing a peptide from the bone protein osteocalcin which interferes with the growth-suppressing inhibition of oxytocin.

AB - Tumor metastatic cells possess a cell-membrane-bound plasminogen activator system. We found that plasmin can cleave the bone-specific protein osteocalcin at arg43-arg44 releasing a carboxy terminal hexapeptide. We tested the biological effect of the C-terminal RFYGPV peptide in MG-63, U2OS, OS9 and OS15 osteosarcoma (OS) cells and found variable growth-promoting effects. Since the sequence of the C-peptide matched the EII region of the oxytocin receptor, we evaluated the OS cells for their response to oxytocin and established a strong growth inhibition by this peptide. This growth effect was substantiated by demonstration, using RT-PCR, of oxytocin receptors (OTR) in OS cells. The presence of OTR was also indicated by immunohistochemical methods. Osteocalcin C-peptide reversed the growth inhibition, however no interaction between oxytocin and C-peptide could be established by several methods aimed to resolve protein-protein interactions. Our results suggest that the plasminogen activator system may participate in the metastatic spread of oxytocin-sensitive tumor cells into skeletal sites by releasing a peptide from the bone protein osteocalcin which interferes with the growth-suppressing inhibition of oxytocin.

UR - http://www.scopus.com/inward/record.url?scp=33749297954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749297954&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 5

ER -